Drugs Made In America Acquisition II Corp. DMII
$10.16
-$0.01-0.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.42M | 1.34M | 1.30M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.42M | 1.34M | 1.30M | -- | -- |
| Operating Income | -1.42M | -1.34M | -1.30M | -- | -- |
| Income Before Tax | 13.02M | 8.58M | 4.19M | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.02 | 8.58 | 4.19 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.02M | 8.58M | 4.19M | -- | -- |
| EBIT | -1.42M | -1.34M | -1.30M | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.20 | 0.13 | 0.06 | -- | -- |
| Normalized Basic EPS | 0.12 | 0.08 | 0.03 | -- | -- |
| EPS Diluted | 0.20 | 0.13 | 0.06 | -- | -- |
| Normalized Diluted EPS | 0.12 | 0.08 | 0.03 | -- | -- |
| Average Basic Shares Outstanding | 256.68M | 205.48M | 154.28M | -- | -- |
| Average Diluted Shares Outstanding | 256.68M | 205.48M | 154.28M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |